The Anthrax toxin receptor (ATR) was initially discovered as the tumor endothelial marker 8 (TEM8). This protein, which exists in three isoforms (36, 40, and 60 kDa), is highly expressed in tumor vessels as well as in the vasculature of developing embryos, suggesting that it may normally play a role in angiogenesis. However, it also acts as the receptor for anthrax toxin. Following the binding of this protein by the protective antigen (PA) of anthrax, PA is cleaved and heptamerizes to form the binding site for both edema factor (EF) and lethal factor (LF). This complex is then endocytosed by the cell; acidification in endosomes allows the release of EF and LF into the cytoplasm where they interfere with MAPK signaling and induce apoptosis.

Long Name

Tumor Endothelial Marker 8/Anthrax Toxin Receptor 1

Alternate Names

ANTXR1

Gene Symbol

ANTXR1

Additional TEM8/ANTXR1 Products

Product Documents for TEM8/ANTXR1 Antibody [HRP]

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for TEM8/ANTXR1 Antibody [HRP]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations
Reviews

TEM8/ANTXR1 Antibody [HRP]

Novus Biologicals, part of Bio-Techne | Catalog # AF3886H

Key Product Details

Species Reactivity

Applications

Label

Antibody Source

Concentration

View all TEM8/ANTXR1 Antibodies »

Product Specifications

Immunogen

Specificity

Clonality

Host

Isotype

Applications for TEM8/ANTXR1 Antibody [HRP]

Immunocytochemistry

Immunohistochemistry

Western Blot

Formulation, Preparation, and Storage

Purification

Formulation

Preservative

Concentration

Shipping

Stability & Storage

Background: TEM8/ANTXR1